The work sits off to the side in the aging research archive: nearby are texts on the loss of steering with age, on the death of cancer cells under neutron bombardment, and on aging as a loss of meaning. All of them are looking for common mechanisms of age-related diseases, but this paper takes a step toward practice: it does not merely describe how cells age, it offers specific natural molecules that remove those cells. This continues the line of senolytic research, that is, drugs that selectively kill senescent cells. So far such agents are few, and almost all of them are synthetic or come with serious side effects.
First the authors screened a library of 55 natural compounds on a culture of human stromal cells PSC27, which they had artificially aged with bleomycin. Three salvianolic acids (SAA, SAB, SAE) proved able to kill specifically the senescent cells without affecting the young ones. Then they hunted for the mechanism using protein microarrays, pull-downs with biotinylated probes and mass spectrometry: they found a common target, the enzyme GSTP1. Binding was confirmed by surface plasmon resonance and cellular thermal shift. Next they tested the effect on the signaling pathways of apoptosis and ferroptosis, and finally on mice: first in a model of premature aging after irradiation, then in naturally aged animals at 20 and 24-27 months.
All three compounds selectively killed senescent cells of various types (fibroblasts, endothelium, stem cells) and regardless of the cause of aging: after chemotherapy, an oncogene or replicative exhaustion. Death proceeded along two paths at once: apoptosis and ferroptosis. The key finding was direct binding of salvianolic acids to GSTP1, an antioxidant defense enzyme. Inhibition of GSTP1 launched the JNK/c-Jun cascade, which suppressed the expression of GPX4, the main defender against ferroptosis. In a tumor model, the combination with mitoxantrone shrank the tumor by 49.5% more than chemotherapy alone. In mice with premature aging, the compounds improved physical fitness and memory. In naturally aged mice (24-27 months, which corresponds to 75-90 years in humans), therapy extended median survival by 51.4% and overall lifespan by 10.9% without an increase in disease incidence.
The work differs from neighboring studies in that it does not merely describe a mechanism of aging but provides ready-made molecules with proven senolytic action. This is the first demonstration that phenolic acids are a distinct class of natural senolytics, not just antioxidants. The discovery of a dual death mechanism (apoptosis and ferroptosis) through GSTP1 broadens our picture of the protective networks of senescent cells: they are resistant not only to apoptosis but also to ferroptosis. This changes the strategy for finding new senolytics: it is now possible to target ferroptotic protection, not only antiapoptotic pathways.
The topic could develop along several lines. First, the molecules themselves need optimization: better bioavailability, a lower effective dose, more stable analogs. Second, it is important to check whether the mechanism works in other cell types and in other species, including primates. Third, it remains to be clarified how GSTP1 fits into the overall survival network of senescent cells and whether there are other targets that could be combined to boost the effect.
The results could influence gerontology (new senolytics for extending healthy life), oncology (overcoming chemoresistance by clearing senescent cells from the tumor microenvironment) and the pharmacology of natural compounds (expanding the arsenal of safe senolytics).
The immediate steps are a phase I clinical trial on the safety and tolerability of salvianolic acids in humans, as well as preclinical studies in primates to verify efficacy and mechanism.
The work is directly tied to an unsolved problem in gerontology: how to extend healthy life, not just lifespan. Senescent cells are one of the key targets, but until now there were no safe and affordable senolytics of natural origin. This study fills that niche and at the same time raises a new question: why are senescent cells protected against two death pathways at once, and how is this double protection regulated.
Salvianolic acids are not new substances. They have long been known in traditional Chinese medicine as components of red-rooted salvia, which was used for centuries to treat cardiovascular disease. Now it turns out that these same molecules may fight aging.
The idea of selectively destroying senescent cells echoes Aldous Huxley's novel Brave New World, where society fights aging with chemical drugs. In the book, though, this leads to a dystopia, whereas here it leads to hope for a healthy old age.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.